Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuneering Corporation - Class A Common Stock
(NQ:
IMRX
)
1.520
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.520
Bid (Size)
1.400 (16)
Ask (Size)
1.530 (1)
Prev. Close
1.520
Today's Range
1.520 - 1.520
52wk Range
1.000 - 6.210
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
February 06, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 03, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Performance
YTD
-31.22%
-31.22%
1 Month
-18.28%
-18.28%
3 Month
-28.97%
-28.97%
6 Month
+17.83%
+17.83%
1 Year
-74.04%
-74.04%
More News
Read More
Maximize Your Trades: Pre-Market Insights And Key Stock Breakdowns
January 13, 2025
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Why Is Immuneering Stock Trading Higher On Tuesday?
January 07, 2025
Via
Benzinga
Why is Immuneering (IMRX) Stock Up 24% Today?
August 01, 2024
Via
InvestorPlace
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
January 13, 2025
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 07, 2025
Via
Benzinga
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
January 07, 2025
From
Immuneering Corporation
Via
GlobeNewswire
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
December 20, 2024
Via
Talk Markets
Topics
Stocks / Equities
Immuneering Launches Pancreatic Cancer Advisory Board
December 19, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Top Trade Picks Of The Day: Don’t Miss These Market Movers
December 17, 2024
Via
Talk Markets
Topics
Stocks / Equities
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
December 13, 2024
Via
Benzinga
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced Melanoma
December 12, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
November 27, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 13, 2024
From
Immuneering Corporation
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
October 18, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 15, 2024
Via
Benzinga
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024
From
Immuneering Corporation
Via
GlobeNewswire
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
October 02, 2024
Via
Benzinga
Why Is Nanocap Immuneering Stock Trading Higher On Friday?
September 13, 2024
Via
Benzinga
Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients
September 12, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024
From
Immuneering Corporation
Via
GlobeNewswire
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
August 01, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.